- Home
- ASTS vs GMAB Comparison
ASTS vs GMAB Comparison
Compare ASTS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTS
- GMAB
- Stock Information
- Founded
- ASTS 2019
- GMAB 1999
- Country
- ASTS United States
- GMAB Denmark
- Employees
- ASTS N/A
- GMAB N/A
- Industry
- ASTS Telecommunications Equipment
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ASTS Consumer Discretionary
- GMAB Health Care
- Exchange
- ASTS Nasdaq
- GMAB Nasdaq
- Market Cap
- ASTS 20.3B
- GMAB 17.4B
- IPO Year
- ASTS N/A
- GMAB N/A
- Fundamental
- Price
- ASTS $81.75
- GMAB $29.16
- Analyst Decision
- ASTS Hold
- GMAB Strong Buy
- Analyst Count
- ASTS 8
- GMAB 7
- Target Price
- ASTS $54.32
- GMAB $41.17
- AVG Volume (30 Days)
- ASTS 17.5M
- GMAB 2.8M
- Earning Date
- ASTS 11-10-2025
- GMAB 11-06-2025
- Dividend Yield
- ASTS N/A
- GMAB N/A
- EPS Growth
- ASTS N/A
- GMAB 77.72
- EPS
- ASTS N/A
- GMAB 21.62
- Revenue
- ASTS $4,892,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- ASTS $1,269.35
- GMAB $24.25
- Revenue Next Year
- ASTS $339.19
- GMAB $16.29
- P/E Ratio
- ASTS N/A
- GMAB $1.35
- Revenue Growth
- ASTS 249.43
- GMAB 32.97
- 52 Week Low
- ASTS $17.50
- GMAB $17.24
- 52 Week High
- ASTS $102.79
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- ASTS 59.42
- GMAB 41.71
- Support Level
- ASTS $66.67
- GMAB $28.83
- Resistance Level
- ASTS $89.64
- GMAB $30.24
- Average True Range (ATR)
- ASTS 6.92
- GMAB 0.66
- MACD
- ASTS -1.64
- GMAB -0.59
- Stochastic Oscillator
- ASTS 41.74
- GMAB 6.85
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.